All News
Links:
Links:
Microbiome of Hip and Knee Osteoarthritis is not "Sterile"
Next-generation DNA sequencing (NGS) techniques show the presence of bacterial DNA in surgical specimens of hip and knee arthritis, from patients undergoing first-time total joint arthroplasty, reports a study in The Journal of Bone & Joint Surgery.
Read ArticleRomosuzumab and Low Sclerostin Levels Underlie CV Risk
New research highlights potential safety concerns around women taking romosozumab, a new anti-osteoporosis drug available on the NHS.
Read Article25 Great Women in Rheumatology
This week I reached out to many leaders in rheumatology and asked: who are the great women in rheumatology who should be recognized? This was prompted by a smart article in Annals of Rheumatic Disease written by Drs. Tuhina Neogi (Boston) and Nicola Dalbeth (N. Zealand), entitled "Where are the women ‘Heroes and Pillars of Rheumatology’?
Read ArticleClinical Profile of RA-associated Interstitial Lung Disease
A prospective, cross-sectional analysis of patients with rheumatoid arthritis (RA) shows those with interstitial lung disease (ILD) tend to be older, obese and have a smoking history.
Read ArticleTofacitinib May Reduce Interstitial Lung Disease Risk in RA
Tofacitinib (Xeljanz) in patients with rheumatoid arthritis (RA) stood out among several other biologic and targeted synthetic disease-modifying antirheumatic drugs (sDMARDs) when it came to the incidence of interstitial lung disease (ILD), a retrospective cohort study showed.
Read ArticleSpondyloarthritis Innovations
The second day of RheumNow Live 2023 ended with a focus on axial spondyloarthritis, especially on the evaluation of the definition of the disease, the inheritance of it, and of course the treatment of it.
Read ArticleWithout DMARDS, Shoulder Arthroplasty Increasing in Rheumatoid Arthritis
The need for total shoulder arthroplasty (TSA) in rheumatoid arthritis (RA) patients appears to depend on the use of disease modifying antirheumatic drugs (DMARDs), according to Seminars in Arthroplasty.
Read ArticleLinks:
Dr. John Cush RheumNow ( View Tweet)
Novel Proteomic Biomarker Set in Osteoarthritis
NIH funded researchers from Duke University have developed a set of serum proteomic biomarkers that successfully predict clinically relevant knee osteoarthritis (KOA) progression (both structural change and joint pain) over a 2 year period.
Read ArticleWomen at high risk of fracture remain untreated for osteoporosis
An estimated 100,000 to 120,000 fragility fractures occur annually in the Netherlands, the equivalent of at least 11 broken bones per hour.
Read ArticleSimon Says “Don’t Do This” (1.27.2022)
Dr. Jack Cush reviews this week’s journal articles, focuses on studies that should not have been done and responds to viewer questions in Ask Cush Anything.
Read ArticleBlood Test Identifies Osteoarthritis Progression
A new blood test that can identify progression of osteoarthritis in the knee is more accurate than current methods, providing an important tool to advance research and speed discovery of new therapies.
Read ArticlePsA Til Death Do Us Part (1.20.2023)
Dr. Jack Cush reviews the highlights from the past week on RheumNow.com.
Read ArticlePhase III Trials Back Bimekizumab for Spondyloarthritis
Bimekizumab, an investigational biologic drug targeting interleukin (IL)-17A/F, appeared highly effective in patients with axial spondyloarthritis (axSpA), researchers said.
Read ArticlePoorer health outcomes for at-risk patients with fractures
People at high risk of fracture who also have complex or multiple chronic medical conditions are less likely to receive treatment for the underlying osteoporosis and also have poorer health outcomes, according to a new study from the Garvan Institute of Medical Research.
Read Article